We recently published a list of Top 10 Stocks on Jim Cramer’s Radar as Trump Tariffs Wreak Havoc Across Global Markets. In ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Hone Health reports that, when it comes to slowing aging and extending lifespan, few interventions are as well-supported by ...

Meghan Trainor has revealed she has Mounjaro to thank for her new look alongside diet and exercise but she's not the only one ...

Among patients with asthma and obesity, about a quarter of encounters include obesity management, according to a poster at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy ...

New York’s reputation as a trailblazer for health equity is in danger. We must ensure equity in obesity treatment.

A concerning number of newly diagnosed patients discontinue their medication within a year. Nearly 40% of patients diagnosed ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.